Browse

Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy

Cited 34 time in Web of Science Cited 36 time in Scopus
Authors
Keam, Bhumsuk; Im, Seock-Ah; Kim, Hee-Jun; Oh, Do-Youn; Kim, Jee Hyun; Lee, Se-Hoon; Chie, Eui Kyu; Han, Wonshik; Kim, Dong-Wan; Cho, Nariya; Moon, Woo Kyung; Kim, Tae-You; Park, In Ae; Noh, Dong-Young; Heo, Dae Seog; Ha, Sung Whan; Bang, Yung-Jue
Issue Date
2009-07
Publisher
Springer Verlag
Citation
Breast Cancer Research and Treatment, Vol.116 No.1, pp.153-160
Keywords
Nodal ratioNeoadjuvant chemotherapyPrognosisBreast cancerNodal stage
Abstract
Purpose Neoadjuvant chemotherapy may modify the yield of involved axillary lymph nodes. The purpose of this study was to identify the clinical significance of the involved nodal ratios in patients with stage II/III breast cancer treated with neoadjuvant chemotherapy. Methods Two hundred and five stage II and III breast cancer patients who received neoadjuvant docetaxel/doxorubicin chemotherapy were enrolled in this prospective study. The patients received three cycles of neoadjuvant chemotherapy followed by curative surgery, either breast-conserving surgery or mastectomy with axillary lymph node dissection, and received three additional cycles of docetaxel/doxorubicin chemotherapy as adjuvant. Adjuvant radiotherapy and hormonal therapy were given after adjuvant chemotherapy when indicated. Results The median follow-up duration was 28.9 months. The overall response rate (RR) for neoadjuvant chemotherapy was 77.6%. The mean nodal ratio was 0.29 (range, 0-1.0; nodal ratio a parts per thousand currency sign0.25, 121 [59.0%] vs. > 0.25, 84 [41.0%]). Relapse free survival (RFS) of the patients who had a nodal ratio > 0.25 was significantly shorter (Hazard Ratio (HR) = 2.701, P = 0.001). A nodal ratio > 0.25 was also associated with a shorter overall survival (OS) (HR = 4.109, P = 0.006). However, RFS and OS were not different according to the absolute number of involved nodes (ANIN) (P = 0.166, P = 0.248, respectively). In multivariate analysis, the nodal ratio was an independent prognostic factor for RFS and OS (HR = 4.246, P < 0.001; HR = 7.764, P < 0.001). Conclusion Axillary nodal ratios have an independent prognostic value in stage II/III breast cancer treated with neoadjuvant chemotherapy. Nodal ratio might be a useful tool to identify the patients at high risk of relapse in the neoadjuvant setting.
ISSN
0167-6806
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18787948

http://www.springerlink.com/content/2v6577t030102080/fulltext.pdf

http://hdl.handle.net/10371/68216
DOI
https://doi.org/10.1007/s10549-008-0160-9
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Cancer Research Institute (암연구소)Journal Papers (저널논문_암연구소)
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse